Figure 10

Response to immunotherapy and chemotherapy. (A–D) Response to treatment with CTLA-4 and PD-1 inhibitors. (E–J) Sensitivity of chemotherapeutic agents A-443654, DMOG, GSK690693, Navitoclax, Temozolomide, and ZSTK474 in the high- and low-risk groups.